<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324009</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000388</org_study_id>
    <secondary_id>5P30AI060354-14</secondary_id>
    <nct_id>NCT03324009</nct_id>
  </id_info>
  <brief_title>2-stage Cervical Cancer Screening in Botswana</brief_title>
  <official_title>Development of a Two-stage Cervical Cancer Screening Algorithm for Botswana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer is the leading cause of cancer death among women in Botswana. The burden of
      cervical cancer is largely related to the high prevalence of HIV in Botswana (22%), as HIV is
      known to be a significant risk factor for cervical cancer. Cervical cancer screening is
      life-saving and has been shown to reduce cervical cancer incidence in multiple settings. Yet,
      there is no consensus on appropriate screening algorithms for women living with HIV, across
      resource settings. Botswana is in a unique position, relative to its neighbors in Sub-Saharan
      Africa, in that there exists capacity for advanced screening modalities, including primary
      high risk human papilloma virus (hrHPV) testing and cytology-based screening. To address this
      issue, this study seeks to evaluate two-stage cervical cancer screening algorithms for
      HIV-positive women in Botswana using hrHPV testing. The two protocols include hrHPV testing
      followed by Pap Smear evaluation and hrHPV testing followed by VIA. The evidence generated
      will be critical to guiding cervical cancer screening in HIV-infected women across resource
      settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical cancer screening programs vary across settings and there is no clear guidance for
      effective screening programs for HIV-positive women. Evaluating the performance of algorithms
      that include human papillomavirus (HPV) DNA testing as first stage screening in high HIV
      prevalence settings like Botswana is essential for establishing an evidence-based strategy
      for cervical cancer screening in HIV-positive women.

      This study seeks to evaluate sensitivity, specificity, and positive predictive value (PPV) of
      two different two-stage cervical cancer screening algorithms for HIV-positive women in
      Botswana: HPV followed by Papanicolaou (Pap) smear, and HPV followed by visual inspection
      with acetic acid (VIA). The specific aims are:

        1. To determine the sensitivity, specificity, and PPV of a two-stage screening algorithm
           that utilizes HPV testing followed by Pap smear for the detection of high-grade cervical
           dysplasia, using colposcopy with histology as the gold standard.

        2. To determine the sensitivity, specificity, and PPV of a two-stage screening algorithm
           that utilizes HPV testing followed by VIA for the detection of high-grade cervical
           dysplasia, using colposcopy with histology as the gold standard.

      The study will enroll 300 HIV positive women. For all 300 participants, gynecologic speculum
      exam will be performed and provider-collected cervical swabs will be collected for HPV
      testing and Pap smear preparation. HPV testing will be performed with either the
      commercially-available Cepheid Xpert® HPV Assay or the commercially-available Roche Cobas®
      HPV Assay. Pap smear will be prepared using standard technique at the site of collection.

      Participants who test HPV-negative will have their Pap smear sent to the National Health Lab
      (NHL) for staining and pathologist evaluation. If the Pap smear is abnormal, they will be
      referred to colposcopy per current Botswana Cervical Cancer guidelines.

      Participants who test HPV-positive will also have their Pap smear reviewed, and will also be
      asked to return for colposcopy and will undergo further diagnosis and treatment for cervical
      cancer per national guidelines. At the colposcopy visit, a trained nurse will conduct VIA
      using the Botswana standard protocol. After application of acetic acid to the cervix, the
      nurse will record visual results as positive or negative. If VIA is positive based on
      assessment of the lesion(s), the nurse will record a recommendation for either cryotherapy or
      loop electrosurgical excision procedure (LEEP). Since all of these HPV-positive participants
      will undergo colposcopy, the participants will not be informed of the VIA results, as neither
      cryotherapy nor LEEP will be administered based on the VIA results. Rather, the participants
      will proceed to colposcopy and results of colposcopy will determine further diagnosis and
      treatment. This design enables us to assess the utility of both HPV/Pap and HPV/VIA two-stage
      algorithms while providing the highest-quality follow-up to cervical cancer screening
      abnormalities in Botswana.

      Participants will thus have a total of two study-related encounters if they are HPV
      positive—one for initial HPV and Pap specimen collection and then one for VIA and colposcopy.
      Participants who are HPV negative and Pap smear negative will only have the one study-related
      initial screening visit. Participants who are HPV negative and Pap smear positive will be
      referred to colposcopy per Botswana cervical cancer screening protocol.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cross-sectional study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of HPV-Pap screening algorithm</measure>
    <time_frame>2 months</time_frame>
    <description>Measurement of the sensitivity, specificity and positive predictive value of Pap smear in predicting cervical precancer and cancer in HPV positive, HIV positive women.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance of HPV-VIA screening algorithm</measure>
    <time_frame>2 months</time_frame>
    <description>Measurement of the sensitivity, specificity and positive predictive value of VIA in predicting cervical precancer and cancer in HPV positive, HIV positive women.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>2-stage screen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be enrolled in the two-stage cervical cancer screening protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>2-stage screen</intervention_name>
    <description>Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.</description>
    <arm_group_label>2-stage screen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥25 years of age

          -  HIV-positive

          -  Competent to understand study procedures and give informed consent.

        Exclusion Criteria:

          -  Currently pregnant

          -  Currently menstruating or having persistent vaginal discharge

          -  Previous hysterectomy

          -  Previous diagnosis of cervical cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Luckett, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Luckett, MD MPH</last_name>
    <phone>+267 7433 3773</phone>
    <email>rluckett@aphmfp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katharine Esselen, MD MBA</last_name>
    <phone>1-617-939-6406</phone>
    <email>kesselen@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <link>
    <url>http://who.int/cancer/country-profiles/bwa_en.pdf</url>
    <description>Cervical cancer statistics in Botswana</description>
  </link>
  <link>
    <url>http://globocan.iarc.fr</url>
    <description>Worldwide cervical cancer statistics</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S2405852115000038</url>
    <description>Xpert HPV performance</description>
  </link>
  <link>
    <url>http://ascopubs.org/doi/full/10.1200/JGO.2016.008011</url>
    <description>Sensitivity of cervical cytology in low- and middle-income countries</description>
  </link>
  <link>
    <url>http://pinkribbonredribbon.org/where-we-work/botswana/</url>
    <description>Overview of Botswana's National Cervical Cancer Screening Program</description>
  </link>
  <reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </reference>
  <reference>
    <citation>Grover S, Raesima M, Bvochora-Nsingo M, Chiyapo SP, Balang D, Tapela N, Balogun O, Kayembe MK, Russell AH, Monare B, Tanyala S, Bhat J, Thipe K, Nchunga M, Mayisela S, Kizito B, Ho-Foster A, Gaolebale BE, Gaolebale PA, Efstathiou JA, Dryden-Peterson S, Zetola N, Hahn SM, Robertson ES, Lin LL, Morroni C, Ramogola-Masire D. Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs. Front Oncol. 2015 Nov 3;5:239. doi: 10.3389/fonc.2015.00239. eCollection 2015. Review.</citation>
    <PMID>26579491</PMID>
  </reference>
  <reference>
    <citation>Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, Wright TC Jr. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000 Feb 23;283(8):1031-7.</citation>
    <PMID>10697063</PMID>
  </reference>
  <reference>
    <citation>Chin KM, Sidhu JS, Janssen RS, Weber JT. Invasive cervical cancer in human immunodeficiency virus-infected and uninfected hospital patients. Obstet Gynecol. 1998 Jul;92(1):83-7.</citation>
    <PMID>9649099</PMID>
  </reference>
  <reference>
    <citation>Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013 May 24;2:35. doi: 10.1186/2046-4053-2-35. Review.</citation>
    <PMID>23706117</PMID>
  </reference>
  <reference>
    <citation>Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol. 2011;4(Suppl 1):S2-S11.</citation>
    <PMID>21617785</PMID>
  </reference>
  <reference>
    <citation>de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012 Jun;13(6):607-15. doi: 10.1016/S1470-2045(12)70137-7. Epub 2012 May 9. Review.</citation>
    <PMID>22575588</PMID>
  </reference>
  <reference>
    <citation>McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008 May;9(5):425-34. doi: 10.1016/S1470-2045(08)70103-7. Epub 2008 Apr 11.</citation>
    <PMID>18407790</PMID>
  </reference>
  <reference>
    <citation>Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am. 2008 Dec;35(4):519-36; vii. doi: 10.1016/j.ogc.2008.09.006. Review.</citation>
    <PMID>19061814</PMID>
  </reference>
  <reference>
    <citation>Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012 Nov 20;30 Suppl 5:F168-74. doi: 10.1016/j.vaccine.2012.06.045. Review.</citation>
    <PMID>23199960</PMID>
  </reference>
  <reference>
    <citation>de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007 Jul;7(7):453-9. Review.</citation>
    <PMID>17597569</PMID>
  </reference>
  <reference>
    <citation>Banura C, Franceschi S, Doorn LJ, Arslan A, Wabwire-Mangen F, Mbidde EK, Quint W, Weiderpass E. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis. 2008 Feb 15;197(4):555-62. doi: 10.1086/526792.</citation>
    <PMID>18237268</PMID>
  </reference>
  <reference>
    <citation>Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA. 2007 Feb 28;297(8):813-9.</citation>
    <PMID>17327523</PMID>
  </reference>
  <reference>
    <citation>Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003 Jan 13;88(1):63-73.</citation>
    <PMID>12556961</PMID>
  </reference>
  <reference>
    <citation>Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007 Aug 1;121(3):621-32.</citation>
    <PMID>17405118</PMID>
  </reference>
  <reference>
    <citation>de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15.</citation>
    <PMID>20952254</PMID>
  </reference>
  <reference>
    <citation>Ramogola-Masire D, McGrath CM, Barnhart KT, Friedman HM, Zetola NM. Subtype distribution of human papillomavirus in HIV-infected women with cervical intraepithelial neoplasia stages 2 and 3 in Botswana. Int J Gynecol Pathol. 2011 Nov;30(6):591-6. doi: 10.1097/PGP.0b013e31821bf2a6.</citation>
    <PMID>21979597</PMID>
  </reference>
  <reference>
    <citation>Macleod IJ, O'Donnell B, Moyo S, Lockman S, Shapiro RL, Kayembe M, van Widenfelt E, Makhema J, Essex M, Wester C. Prevalence of human papillomavirus genotypes and associated cervical squamous intraepithelial lesions in HIV-infected women in Botswana. J Med Virol. 2011 Oct;83(10):1689-95. doi: 10.1002/jmv.22178.</citation>
    <PMID>21837784</PMID>
  </reference>
  <reference>
    <citation>Ginsburg O, Badwe R, Boyle P, Derricks G, Dare A, Evans T, Eniu A, Jimenez J, Kutluk T, Lopes G, Mohammed SI, Qiao YL, Rashid SF, Summers D, Sarfati D, Temmerman M, Trimble EL, Padela AI, Aggarwal A, Sullivan R. Changing global policy to deliver safe, equitable, and affordable care for women's cancers. Lancet. 2017 Feb 25;389(10071):871-880. doi: 10.1016/S0140-6736(16)31393-9. Epub 2016 Nov 1. Review.</citation>
    <PMID>27814964</PMID>
  </reference>
  <reference>
    <citation>Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011 Nov 26;378(9806):1868-73. doi: 10.1016/S0140-6736(11)61522-5. Epub 2011 Nov 1.</citation>
    <PMID>22051739</PMID>
  </reference>
  <reference>
    <citation>Chatzistamatiou K, Moysiadis T, Angelis E, Kaufmann A, Skenderi A, Jansen-Duerr P, Lekka I, Kilintzis V, Angelidou S, Katsiki E, Hagemann I, Tsertanidou A, Koch I, Boecher O, Soutschek E, Maglaveras N, Agorastos T. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study. Arch Gynecol Obstet. 2017 May;295(5):1247-1257. doi: 10.1007/s00404-017-4324-x. Epub 2017 Mar 23.</citation>
    <PMID>28337594</PMID>
  </reference>
  <reference>
    <citation>Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006 Sep 1;119(5):1095-101.</citation>
    <PMID>16586444</PMID>
  </reference>
  <reference>
    <citation>Jeronimo J, Castle PE, Temin S, Shastri SS. Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract. 2017 Feb;13(2):129-133. doi: 10.1200/JOP.2016.017889. Epub 2016 Nov 15.</citation>
    <PMID>27845871</PMID>
  </reference>
  <reference>
    <citation>Wright TC Jr, Ellerbrock TV, Chiasson MA, Van Devanter N, Sun XW. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol. 1994 Oct;84(4):591-7.</citation>
    <PMID>8090399</PMID>
  </reference>
  <reference>
    <citation>Mustafa RA, Santesso N, Khatib R, Mustafa AA, Wiercioch W, Kehar R, Gandhi S, Chen Y, Cheung A, Hopkins J, Ma B, Lloyd N, Wu D, Broutet N, Schünemann HJ. Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy. Int J Gynaecol Obstet. 2016 Mar;132(3):259-65. doi: 10.1016/j.ijgo.2015.07.024. Epub 2015 Nov 12. Review.</citation>
    <PMID>26851054</PMID>
  </reference>
  <reference>
    <citation>Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, Nouhou H, Sakande B, Wesley R, Somanathan T, Sharma A, Shastri S, Basu P. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer. 2008 Jul 1;123(1):153-60. doi: 10.1002/ijc.23489.</citation>
    <PMID>18404671</PMID>
  </reference>
  <reference>
    <citation>Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007 Aug 4;370(9585):398-406.</citation>
    <PMID>17679017</PMID>
  </reference>
  <reference>
    <citation>Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014 Feb 8;383(9916):524-32. doi: 10.1016/S0140-6736(13)62218-7. Epub 2013 Nov 3. Erratum in: Lancet. 2015 Oct 10;386(10002):1446.</citation>
    <PMID>24192252</PMID>
  </reference>
  <reference>
    <citation>Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med. 2009 Apr 2;360(14):1385-94. doi: 10.1056/NEJMoa0808516.</citation>
    <PMID>19339719</PMID>
  </reference>
  <reference>
    <citation>Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA. 2005 Nov 2;294(17):2173-81.</citation>
    <PMID>16264158</PMID>
  </reference>
  <reference>
    <citation>Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010 Oct 20;102(20):1557-67. doi: 10.1093/jnci/djq342. Epub 2010 Sep 30.</citation>
    <PMID>20884893</PMID>
  </reference>
  <reference>
    <citation>Denny LA, Sankaranarayanan R, De Vuyst H, Kim JJ, Adefuye PO, Alemany L, Adewole IF, Awolude OA, Parham G, de Sanjosé S, Bosch FX. Recommendations for cervical cancer prevention in sub-saharan Africa. Vaccine. 2013 Dec 29;31 Suppl 5:F73-4. doi: 10.1016/j.vaccine.2012.11.077.</citation>
    <PMID>24331750</PMID>
  </reference>
  <reference>
    <citation>Santesso N, Mustafa RA, Schünemann HJ, Arbyn M, Blumenthal PD, Cain J, Chirenje M, Denny L, De Vuyst H, Eckert LO, Forhan SE, Franco EL, Gage JC, Garcia F, Herrero R, Jeronimo J, Lu ER, Luciani S, Quek SC, Sankaranarayanan R, Tsu V, Broutet N; Guideline Support Group. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. Int J Gynaecol Obstet. 2016 Mar;132(3):252-8. doi: 10.1016/j.ijgo.2015.07.038. Epub 2015 Dec 14.</citation>
    <PMID>26868062</PMID>
  </reference>
  <reference>
    <citation>Denny L, Kuhn L, Risi L, Richart RM, Pollack A, Lorincz A, Kostecki F, Wright TC Jr. Two-stage cervical cancer screening: an alternative for resource-poor settings. Am J Obstet Gynecol. 2000 Aug;183(2):383-8.</citation>
    <PMID>10942474</PMID>
  </reference>
  <reference>
    <citation>Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.</citation>
    <PMID>19141778</PMID>
  </reference>
  <reference>
    <citation>Bigoni J, Gundar M, Tebeu PM, Bongoe A, Schäfer S, Fokom-Domgue J, Catarino R, Tincho EF, Bougel S, Vassilakos P, Petignat P. Cervical cancer screening in sub-Saharan Africa: a randomized trial of VIA versus cytology for triage of HPV-positive women. Int J Cancer. 2015 Jul 1;137(1):127-34. doi: 10.1002/ijc.29353. Epub 2014 Dec 5.</citation>
    <PMID>25420434</PMID>
  </reference>
  <reference>
    <citation>Ramogola-Masire D, de Klerk R, Monare B, Ratshaa B, Friedman HM, Zetola NM. Cervical cancer prevention in HIV-infected women using the &quot;see and treat&quot; approach in Botswana. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):308-13. doi: 10.1097/QAI.0b013e3182426227.</citation>
    <PMID>22134146</PMID>
  </reference>
  <reference>
    <citation>Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst. 2000 May 17;92(10):818-25.</citation>
    <PMID>10814677</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Rebecca Luckett</investigator_full_name>
    <investigator_title>Instructor in Obstetrics, Gynecology and Reproductive Biology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

